Spindle Cell Oncocytoma of the Anterior Pituitary Presenting with an Acute Clinical Course Due To Intraventricular Hemorrhage. A Case Report and Review of Literature

Mostafa Osman
Andrew Wild

Corresponding Author: Mostafa Osman, e-mail: mosman@fakeeh.care

Conflict of interest: None declared

Patient: Male, 56
Final Diagnosis: Spindle cell oncocytoma of the adenohypophysis
Symptoms: Disturbed conscious level • visual disturbances
Medication: —
Clinical Procedure: Urgent craniotomy
Specialty: Neurosurgery

Objective: Rare disease

Background: Spindle cell oncocytoma (SCO) is a rare nonfunctioning neoplasm of the adenohypophysis, and was first described in 2002. SCO has been categorized as a separate entity by the 2007 World Health Organization (WHO) and is classified as a Grade 1 tumor of the central nervous system (CNS). Review of the literature has shown that 33 cases of SCO have been reported to date, and most of them presented with a mass effect or with panhypopituitarism. However, all reported cases have described the tendency of SCO to be hypervascular on imaging and histology. We detail the first reported case of SCO to present with acute symptoms (pituitary apoplexy) and intraventricular hemorrhage, and review the literature on SCO.

Case Report: We report the case of 56-year-old man who presented suddenly with a severe headache and an altered level of consciousness. Brain magnetic resonance imaging (MRI) showed a suprasellar mass with hemorrhagic areas within the tumor and bleeding into the lateral ventricle with chiasmal and hypothalamic compression. The patient underwent urgent craniotomy, tumor resection and placement of an external ventricular drain (EVD). Histology and immunohistochemistry supported a diagnosis of SCO.

Conclusions: SCO of the adenohypophysis should be considered in patients who present suddenly with symptoms of pituitary apoplexy and intraventricular hemorrhage which may worsen the prognosis.

MeSH Keywords: Brain Neoplasms • Pituitary Apoplexy • Pituitary Neoplasms

Full-text PDF: https://www.amjcaserep.com/abstract/index/idArt/903702
Primary tumors of the anterior pituitary, or adenohypophysis, account for between 10% and 15% of all intracranial tumors. The spectrum of tumors at this site includes the most common, the pituitary adenoma, followed by craniopharyngioma, meningioma, oncocytoma, pituitary tumor and granular cell tumor [1].

SCO of the adenohypophysis is a rare, benign, primary tumor in the sellar region, accounting for 0.1%–0.4% of all sellar tumors [2]. SCO was described as a new entity in 2002 by Roncaroli and colleagues and was classified as a distinct non-adenomatous sellar mass in the 2007 World Health Organization (WHO) classification [3,4].

Due to its rarity, little information is available regarding the imaging features and surgical characteristics of SCO. To our knowledge, there are only 34 cases reported to date (including our case). Most cases present with symptoms of slow onset that progress with as the tumor increases in size, resulting in compression of surrounding structures. Few cases presented with acute symptoms. Our case report is the first to describe a case presenting clinically with intratumoral bleeding and hemorrhage into the ventricles.

Case Report

A 56-year-old man presented to the emergency room (ER) with acute onset of a severe headache, vomiting, neck pain, back pain, and reduced level of consciousness. His son reported recently impaired visual acuity. On examination, the patient was stable and the Glasgow Coma Scale (GCS) score was 13/15 with no other neurological deficit. Following initial management in ER, the patient was sent for further investigations.

Magnetic resonance imaging (MRI) of the brain was performed using a 1.5 Tesla Siemens Avanto scanner. Multi-planar, multi-sequence images were obtained. Brain MRI showed a sellar and suprasellar macro-adenoma measuring 2.5×4.4×2.5 cm in its maximum anteroposterior, craniocaudal, and transverse dimensions, respectively, with intralesional bleeding, and intraventricular hemorrhage extending into the fourth ventricle. Mild ventricular system dilatation was also noted, with chiasmal and hypothalamic compression (Figures 1, 2).

The patient went for urgent sub-frontal craniotomy for tumor resection and placement of an external ventricular drain (EVD). Intra-operative tumor hypervascularity gave the macroscopic appearance of meningioma, and profuse bleeding limited the surgical resection. A sample of cerebrospinal fluid (CSF) was sent for analysis, and the tumor specimen was sent for histopathological examination and microbiological culture and sensitivity. There were no significant abnormalities found on analysis of the CSF, Gram stain or culture and sensitivity. Light microscopy (Figure 3) with hematoxylin and eosin (H&E) staining showed interfascicles of spindle cells, and epithelioid cells with eosinophilic cytoplasm containing numerous mitochondria (oncocytic change). The absence of cellular atypia, mitoses, invasion, and necrosis, together with a low cell proliferation rate on immunohistochemical staining with antibodies to Ki67 all supported the benign nature of the tumor. Immunohistochemical staining also showed that the tumor cells were uniformly positive for vimentin, S100, epithelial membrane antigen (EMA), and thyroid transcription factor-1 (TTF-1), and focally positive for glial fibrillary acidic protein (GFAP), and was negative for immunostaining with antibodies to CD34, smooth muscle actin (SMA), desmin, and pan-cytokeratin (CK).

Serological findings showed that the basal level of growth hormone (GH) was <0.10 ng/ml, morning cortisol level was 0.9 mg/dl, free triiodothyronine (T3) was 3.49 pmol/L, thyroid stimulating hormone (TSH) was 1.1819 uIU/mL, free thyroxine (T4) was 9.37 pmol/L, prolactin was 15.31 ng/mL, sodium (Na) was 131 mmol/L, and potassium (K) was 3.4 mmol/L.

The patient underwent good recovery with unchanged visual acuity but with a field defect in the left eye. He was referred for radiotherapy to control any residual tumor and showed no tumor recurrence at six-month follow-up.

Discussion

Spindle cell oncocytoma (SCO) is defined as an oncocytic, non-secreting, benign neoplasm of the adenohypophysis that presents in adults, with a mean age at presentation of 56 years [3,4]. These tumors may be indistinguishable macroscopically from a non-functioning pituitary adenoma and follow a benign clinical course, corresponding to World Health Organization (WHO) Grade 1 tumors of the central nervous system (CNS) [4].

Due to its benign clinical course and slow progression, review of the literature has shown that SCO usually presents with visual impairment (20 cases), which was the most common presenting symptom. Panhypopituitarism was the next most common symptom (15 cases) followed by headache (14 cases). Less commonly, SCO presented with vomiting, epistaxis, fatigue, syncope, polyuria, weight loss, oligomenorrhea, and amenorrhea (Table 1). Ablupt neurologic deterioration may result from several etiologies associated with brain tumors, resulting in increased intracranial pressure (ICP). These causes include intracranial hemorrhage, infarction, cerebral edema, hydrocephalus, tissue necrosis, pituitary hemorrhage, and seizures. Pituitary infarction...
and/or subsequent hemorrhage occur mainly from the compression effects of the tumor mass on the hypophyseal arteries against the edges of the sellar diaphragm. The signs and symptoms of pituitary hemorrhage (apoplexy) include abrupt onset of headache, ophthalmoplegia, visual disturbances, and changes in mental status [5].

Although the radiological findings have been reported to be non-specific in the literature, the characteristics of magnetic resonance imaging (MRI) and the different patterns of contrast enhancement may help to recognize this rare tumor. In the recent publication from Hasiloglu and colleagues, they described the radiological findings of SCO, which include hypointense foci and linear signal-void areas on T1-weighted imaging and T2-weighted imaging [6]. On dynamic contrast-enhanced MRI (DCE-MRI) SCO shows intense contrast enhancement during the early stage of contrast administration (Hasiloglu’s sign) [6]. The difficulty in distinguishing SCO from other tumors such as pituitary adenoma is important, because this tumor, unlike pituitary adenoma, tends to be very vascular and prone to hemorrhage during surgical resection [7]. This property of SCO is important to recognize, as hemorrhage can lead to the need...
### Table 1. Review of the literature on reported cases of spindle cell oncocytoma (SCO) of the anterior pituitary (adenohypophysis).

| Year | No. | Age/sex | Symptoms & signs | Imaging | Treatment | Histopathology | Recurrence |
|------|-----|---------|------------------|---------|-----------|----------------|------------|
| Roncaroli et al. [3] | 2002 | 5 | 53–71 years | 5 Pan-hypopituitarism 2/5 Visual field defects | 5/5 Sellar mass with suprasellar extension | Vimentin S/5 EMA 5/5 S-100 4/5 | No recurrence at 3 years |
| Dahiya et al. [14] | 2005 | 2 | 1: 26/ male 2: 55/ female | 1: Visual loss, pan-hypopituitarism 2: Headache, visual loss | 1–2: Sellar/parasellar mass | 1–2: EMA S-100 | 1: Radiotherapy after initial surgery, no growth at 7 years 2: No recurrence at 6 months |
| Kloub et al. [15] | 2005 | 2 | 1: 71/ female 2: 76/ male | 1: Visual loss 2: Epistaxis | 1: Sellar mass with suprasellar extension 2: Sellar mass with extension to nasopharynx | 1: Vimentin EMA S-100 Ki-67 18% 2: Vimentin EMA S-100 Ki-67 20% | 1: Recurrence after 3 years from initial surgery, repeat surgery due to optic chiasm compression. 2: Recurrence after 3 years from initial surgery, received radiation therapy |
| Vajtai et al. [16] | 2006 | 1 | 48/ female | Visual loss | Sellar/parasellar mass with suprasellar extension | Trans-sphenoidal, total resection | Vimentin EMA S-100 | No recurrence at 15 years |
| Farooq et al. [17] | 2008 | 1 | Male/76 | Headache/weakness | Sellar/parasellar mass | Trans-sphenoidal | S-100 and EMA | Radiotherapy after surgery, no growth at 2 years |
| Borota et al. [18] | 2009 | 1 | 55/ female | Headache, hypopituitarism | Sellar/parasellar mass | Trans-sphenoidal, partial resection due to vascularity/bleeding | Vimentin EMA S-100 Ki-67 2% | Growth at 1 year, received radiotherapy, further growth after 10 months, stable afterwards |
| Coire, et al. [19] | 2009 | 1 | 63/ female | Visual loss, headache, pan-hypopituitarism | Sellar/parasellar mass | Trans-sphenoidal, partial resection | Vimentin EMA S-100 | Growth 5 months after initial surgery with optic chiasm compression. Repeat surgery followed radiotherapy |
**Table 1 continued.** Review of the literature on reported cases of spindle cell oncocytoma (SCO) of the anterior pituitary (adenohypophysis).

| Year | No. | Age/sex | Symptoms & signs | Imaging | Treatment | Histopathology | Recurrence |
|------|-----|---------|------------------|---------|-----------|----------------|------------|
| Demssie et al. [20] | 2009 | 1 | 59/male | Visual loss, weight loss, vomiting, fatigue. Pan-hypopituitarism | Sellar/suprasellar mass | Trans-sphenoidal, partial resection; mass was noted to be firm and highly vascular | EMA S-100 Ki-67 1% | Growth at 9 months |
| Matyja et al. [2] | 2010 | 2 | 1: 63/female, 2: 65/female | 1–2: Headache, visual loss, pan-hypopituitarism | 1–2: Sellar/suprasellar mass | 1: Trans-sphenoidal, total resection 2: Frontal approach, total resection | 1–2: Vimentin EMA S-100 | 1: No recurrence at 28 months 2: Recurrence at 3 years, then repeat surgery with no recurrence 20 months after 2nd surgery |
| Borges et al. [21] | 2010 | 1 | 70/female | Visual loss | Sellar mass, heterogeneous features | Trans-sphenoidal resection, extensive bleeding | Vimentin S-100 | Recurrence at 13 years |
| Mlika et al. [22] | 2011 | 1 | 45/female | Visual loss, headache | Sellar/suprasellar mass | Total resection, Trans-sphenoidal | Vimentin EMA S-100 | No recurrence at 3 |
| Romero-Rojas et al. [23] | 2011 | 1 | 42/female | Oligomenorrhea | Sellar mass | Resection | Vimentin EMA S-100 | No follow-up mentioned |
| Ogiwara et al. [13] | 2011 | 1 | 39/male | Headache, visual loss, Pan-hypopituitarism, polyuria | Sellar/suprasellar mass | Trans-sphenoidal, partial resection due to firm and hypervascular mass | S-100 EMA TTF-1 | 1: Followed by radiotherapy with recurrence at 4 months then total resection-no recurrence at 1 year |
| Fujisawa et al. [24] | 2012 | 1 | 68/male | Visual loss, Pan-hypopituitarism | Sellar/suprasellar mass | Trans-sphenoidal, partial resection due to hypervascular and elastic mass | EMA S-100 | Growth at 1.5 years followed by radiotherapy |
| Alexandrescue et al. [12] | 2012 | 1 | 24/female | headache, amenorrhea for 18 months, and new onset of left superior visual field disturbance of the left eye | Sellar/suprasellar | Sub-labial transseptal approach | S100 EMA vimentin | No growth at 6 months |
to stabilize the patient, abort or defer surgery, or to consider embolization of the tumor vasculature [8].

Conservative treatment of pituitary hemorrhage (apoplexy) is rarely associated with reversal of hypopituitarism and may worsen the condition [9]. Open transsphenoidal decompression of the hemorraghic pituitary adenoma is the favored treatment for pituitary hemorrhage [10]. Unlike the trans-frontal approach, no brain retraction is needed, and trans-sphenoidal decompression is better tolerated by severely ill patients. A craniotomy is reserved for patients with a non-aerated sphenoidal sinus, a small sella with a large suprasellar mass, a narrow sellar diaphragm, with a dumb-bell shaped mass, or an associated intracerebral hematoma [11].

Alexendersecu and colleagues have proposed an explanation of why a minority of these tumors present with recurrence after an initial complete resection [12]. The expression of precursor neuronal immunomarkers, such as cytoplasmic pan-neuronal marker, SMI-311, expressed by the spindle cell

| Year   | No. | Age/sex | Symptoms & signs | Imaging                  | Treatment                          | Histopathology       | Recurrence                           |
|--------|-----|---------|------------------|--------------------------|------------------------------------|----------------------|--------------------------------------|
| Singh  | 2012 | 1       | 68/male          | Visual loss, headache    | Sellar/suprasellar mass            | Trans-sphenoidal, partial resection due to firm and hypervascular mass | Vimentin EMA          | No growth at 5 months                |
| Rotman | 2014 | 1       | 80/male          | Visual loss, hypopituitarism, syncope | Sellar/suprasellar mass            | Trans-sphenoidal, total resection | Vimentin EMA          | Total resection/minimal growth at 8 years |
| Zygourakis | 2015 | 2       | 1: 31/female 2: 53/female | 1: Headache, visual loss 2: Headache | 1: Sellar/suprasellar mass 2: Sellar/suprasellar mass | 1: Trans-sphenoidal, partial resection 2: Biopsy, 7-mm lesion | 1: Anti-mitochondrial Ab EMA 2: Anti-mitochondrial Ab EMA S-100 | 1: No recurrence at 6 months 2: No progression in 2 months |
| Mu     | 2015 | 2       | 1: 35/female 2: 62/female | 1: Visual deficit, amenorrhea, galactorrhea 2: n/a | 1: Sellar/suprasellar mass 2: Sellar/suprasellar mass | Total resection, craniotomy | 1–2: Vimentin EMA S-100 TTF-1 | 1–2: No recurrence over 15–21 months |
| Custodio | 2015 | 1       | 60/female        | Severe hyponatremia, pan hypopituitarism, visual deficit | Sellar/suprasellar mass | Trans-sphenoidal, partial resection, vascular mass | EMA S-100 Vimentin TTF-1 | No growth at 18 months |
| Won Hyung | 2015 | 1       | 49/male          | 18-month history of malaise, decreased libido and hot flashes | Sellar/suprasellar | Trans-nasal trans-sphenoidal | vimentin, S100 TTF-1 EMA | |
| Mansour Mathkour | 2015 | 1       | 59/male          | Headache               | Sellar                     | Sub-labial trans-septal trans-sphenoidal | Vimentin, annexin, galectin, and S-100 | No growth at 4 years |
| Huy Gia Vuong et al. | 2016 | 1       | 70/male          | headache and visual Disturbance for 6 months. | Suprasellar-sellar | Trans-sphenoidal approach | Vimentin, TTF-1EMA and galectin-3. S-100 | |
component, nestin and CD44 expressed by the epithelioid or polygonal cells of the tumor, may indicate that SCO of the adenohypophysis has a neuronal origin [12].

There is little evidence in the literature for the sensitivity of SCO to radiotherapy. Four of five published cases of SCO that underwent radiation therapy recurred. Therefore, at this time, no recommendations can be made regarding the effectiveness of adjuvant radiotherapy for SCO, and the effectiveness of stereotactic radiosurgery for treatment of this tumor has not been described [13].

Conclusions

A case of spindle cell oncocytoma (SCO) of the anterior pituitary (adenohypophysis) is presented, which has the unusual feature of an acute presentation (pituitary apoplexy) due to the presence of the intraventricular hemorrhage associated with a large sellar and suprasellar tumor mass. Previously reported cases of SCO have been associated with hypervascularity, and problematic bleeding has been previously reported during surgical resection. Being aware of the possible diagnosis of SCO of the anterior pituitary is of clinical importance.

A review of the literature has shown that there is some evidence to suggest that different imaging patterns from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) may be an aid to distinguishing SCO from other tumors of the adenohypophysis. However, SCO should be considered if peri-tumoral or intraventricular bleeding is present on initial imaging. In such cases, urgent surgery is indicated that should also include management of the effects of intraventricular hemorrhage.

Conflict of interest

None.

References:

1. Kuroasaki M, Saeger W, Lüdecke DK: Pituitary tumors in the elderly. Pathol Res Pract, 2001; 197(1): 493–97
2. Matyja E, Maksymowicz M, Gjakowska W et al: Spindle cell oncocytoma of the adenohypophysis – a clinicopathological and ultrastructural study of two cases. Folia Neuropathol, 2010; 48: 175–84
3. Roncaroli F, Schelthauer BW, Ceracchi G et al: Spindle cell oncocytoma of the adenohypophysis: A tumor of folliculostellate cells? Am J Surg Pathol, 2002; 26(8): 1048–55
4. Louis DN, Ohgaki H, Wiestler OD et al: The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol, 2007; 114(2): 97–109
5. Schneck MJ, Biller J, Loftus CM: Neurosurgical emergencies. In: VanGilder JC. (ed.), Emergency treatment of brain tumors. 2nd ed. New York: Thieme Medical Publishers, Inc.; 2008; 125–28
6. Hasilgouli Z, Ure E, Comunoglu N et al: New radiological clues in the diagnosis of spindle cell oncocytoma of the adenohypophysis. Clin Radiol, 2016; 71(9): 937.e5–937.e11
7. Aquilina K, Kamel M, Kalimuthu SG et al: Granular cell tumour of the nervous system: An unusual case. J Med Case Rep, 2010; 48: 175–84
8. Wolfe SQ, Bruce J, Morcos JJ: Pituicytoma: Case report. Neurosurgery, 2008; 63(1): E173–74
9. Arafa BM, Harrington JF, Madhoun ZT, Selman WR: Improvement of pituitary function after surgical decompression for pituitary tumor apoplexy. J Clin Endocrinol Metab, 1990; 71(2): 323–28
10. Semple PL, Webb MK, de Villiers JC, Laws ER: Pituitary apoplexy. Neurosurgery, 2016; 56(1): 65–73
11. Onesti ST, Wisniewski T, Post KD: Clinical versus subclinical pituitary apoplexy: Presentation, surgical management, and outcome in 21 patients. Neurosurgery, 1990; 26(6): 98–96
12. Alexandrescu S, Brown RE, Tandon N, Bhattacharjee MB: Neuron precursor features of spindle cell oncocytoma of the adenohypophysis. Arch Clin Lab Sci, 2012; 42(2): 123–29
13. Ogwara H, Dubner S, Shafizadeh S et al: Spindle cell oncocytoma of the pituitary and pitucytoma: Two tumors mimicking pituitary adenoma. Surg Neurol Int Neurol Int, 2012; 2: 116
14. Dahiya S, Sarkar C, Hedley-Whyte ET et al: Spindle cell oncocytoma of the adenohypophysis: Report of two cases. Acta Neuropathol, 2005; 110: 97–99
15. Kluss O, Perry A, Tu P-H et al: Spindle cell oncocytoma of the adenohypophysis: Report of two recurrent cases. Am J Surg Pathol, 2005; 29: 247–53
16. Vajalj I, Sahli R, Kappeler A: Spindle cell oncocytoma of the adenohypophysis: Report of a case with a 16-year follow-up. Pathol Pract, 2006; 202: 745–50
17. Farooq MU, Bhatt A, Chang HF: Teaching neuroimage: Spindle cell oncocytoma of the pituitary gland. Neurology, 2008; 71: e3
18. Borota OC, Schelthauer BW, Fougner SL et al: Spindle cell oncocytoma of the adenohypophysis: Report of a case with marked cellular atypia and recurrence despite adjuvant treatment. Clin Neuropathol, 2008; 28: 91–95
19. Coiré CJ, Horvath E, Smyth HS, Kovacs K: Rapidly recurring folliculostellate cell tumor of the adenohypophysis: A review of the literature. J Med Case Rep, 2010; 28: 303–8
20. Demessie YN, Joseph J, Dawson T et al: Recurrent spindle cell oncocytoma of the pituitary, a case report and review of literature. Pituitary, 2011; 14: 367–70
21. Borges MT, Lillehei KO, Kleinschmidt-DeMasters BK: Spindle cell oncocytoma with late recurrence and unique neuroimaging characteristics due to recurrent subclinical intratumoral bleeding. J Neurooncol, 2011; 101: 145–54
22. Milka M, Azzouh H, Chelly I et al: Spindle cell oncocytoma of the adenohypophysis in a woman: A case report and review of the literature. J Med Case Rep, 2011; 5: 64
23. Romero-Rojas AE, Mélir-Urbe MA, Barajas-Solano PA et al: Spindle cell oncocytoma of the adenohypophysis: Brain Tumor Pathol, 2011; 28: 359–64
24. Fujisawa H, Tohya Y, Muramatsu N et al: Spindle cell oncocytoma of the adenohypophysis with marked hypervascularity. Neurol Med Chi (Tokyo), 2012; 52: 594–98
25. Singh G, Agarwal S, Sharma MC et al: Spindle cell oncocytoma of the adenohypophysis: A case report illustrating its natural history with 8-year observation and a review of the literature. Clin Imaging, 2014; 38: 499–504
26. Zygourakis CC, Rolston JD, Lee HS et al: Pituicytomas and spindle cell oncocytomas: Modern case series from the University of California, San Francisco. J Med Case Rep, 2008; 2: 150–58
27. Mu Q, Yu J, Qu L et al: Spindle cell oncocytoma of the adenohypophysis: A case report and review of literature. Mol Med Rep, 2015; 12: 871–76
28. Custodio PJP, Jho DH, Pu C et al: Spindle cell oncocytoma of the pituitary presenting with severe hyponatremia. AACE Clin Case Reports, 2015; 2(3): e237–43

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
30. Ryu WH, Hamilton L, Starreveld Y, Chan J: An unusual oncocytic sellar neoplasm in a patient with Birt-Hogg-Dubé syndrome. Int J Neuropathol, 2015; 3: 43–54

31. Mathkour M, Garces J, Scullin T et al: RARE-08. Spindle cell oncocytoma of the pituitary gland: Case report and literature review. Neuro Oncol, 2015; 17(6): v202

32. Vuong HG, Kondo T, Tran TM et al: Spindle cell oncocytoma of adenohypophysis: Report of a case and immunohistochemical review of literature. Pathol Res Pract 2016; 212: 222–25